Viw Magazine

The Times


.

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - AIM Vaccine (06660.HK) has added good news to the research and development of its heavyweight single product. According to the announcement on December 19, the clinical trial approval for the Group's suspension culture quadrivalent influenza vaccine (MDCK cells) with new technological route and second generation of highly-effective absorbed tetanus vaccine have been recently obtained from the National Medical Products Administration.

Read more …

LifeStyle

New Brisbane Dads Embracing Weekly Baby Classes for Fun and Bonding

If you think baby classes are only for mums and their little ones, think again! New dads across Au...

Signs Your Relationship Needs More Than Just a Date Night

Date nights get a lot of credit. Book a babysitter, go somewhere nice, put the phones away and recon...

Ever Wondered Why Cosmetic Clinics Are So Careful About What They Say Online?

No prices, no product names, no glowing influencer reviews. If cosmetic clinic marketing has ever ...

Honouring Faith and Family: Understanding Traditional Funeral Rites in Australia

Australia's funerals are as varied as its people. On a single day in any capital city, you might fin...

hacklink esim českoHerabetTrBetvpnfree books downloadzlibrarySahabetstreameastnon gamstopBetimselçuksportsgrandpashabet girişgrandpashabet girişdinamobetbetimStreamEastsohbet hattıxspintaraftarium24CrackStreamsholiganbetseo ajansıyurtdışı turseo danışmanlığıseo uzmanıgrandpashabet girişstreameastseo hizmetijojobetgrandpashabetjojobetviagra 100 mg fiyatjojobetjojobetcasibommy gift cardstreameastdeneme bonusu veren siteler 2026casibom